Fraction absorbed (Fabs): Different connotations and confusion for the literature?

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 5, 2011, Pages 301-302

  Sandy Pang, K ^a   Rostami Hodjegan, Amin ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; DRUG;

DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG EXCRETION; DRUG PENETRATION; DRUG TRANSPORT; ENTEROHEPATIC CIRCULATION; FIRST PASS EFFECT; NOTE; CLASSIFICATION; EDITORIAL; HUMAN; INTESTINE ABSORPTION; METABOLISM; NOMENCLATURE; ORAL DRUG ADMINISTRATION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; BIOLOGICAL TRANSPORT; HUMANS; INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS; TERMINOLOGY AS TOPIC;

EID: 79959763854     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.758     Document Type: Note

References (4)

1. Fan J, Chen S, Chow ECY, Pang KS,. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 2010; 11: 743-761.
2. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A,. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the 'advanced dissolution, absorption, metabolism (adam)' model. Curr Drug Metab 2010; 11: 716-729.
3. Sun H, Pang KS,. Physiological modeling to un derstand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 2010; 27: 1237-1254.
4. Shepard TA, Reuning RH, Aarons LJ,. Estimation of area under the curve for drugs subject to enterohepatic cycling. J Pharmacokinet Biopharm 1985; 13: 589-608. (Pubitemid 16136866)